WARNING
id: 415b3da7-3fa0-4a5f-e054-00144ff8d46c
displayName: BOXED WARNING SECTION
FDA Article Code: 34066-1
Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats (see
Precautions
). Spironolactone should be used only in those conditions described under
Indications and Usage
. Unnecessary use of this drug should be avoided.
DESCRIPTION
id: 415b3da7-3fa1-4a5f-e054-00144ff8d46c
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3
Spironolactone oral tablets contain 25 mg, 50 mg, or 100 mg of the aldosterone antagonist spironolactone, 17-hydroxy-7α-mercapto-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone acetate, which has the following structural formula:
Spironolactone is practically insoluble in water, soluble in alcohol, and freely soluble in benzene and in chloroform.
Spironolactone tablets, 25 mg contain the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, crospovidone, docusate sodium 85%/sodium benzoate 15%, entrapped peppermint flavor, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate.
Spironolactone tablets, 50 mg and 100 mg contain the following inactive ingredients: anhydrous lactose, carnauba wax, colloidal silicon dioxide, docusate sodium 85%/sodium benzoate 15%, entrapped peppermint flavor, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, povidone, sodium starch glycolate, titanium dioxide, and triacetin.
INDICATIONS AND USAGE
id: 415b3da7-3fa8-4a5f-e054-00144ff8d46c
displayName: INDICATIONS & USAGE SECTION
FDA Article Code: 34067-9
Spironolactone is indicated in the management of:
Primary hyperaldosteronism for:
Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial.
Short-term preoperative treatment of patients with primary hyperaldosteronism.
Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery.
Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism).
Edematous conditions for patients with:
CONTRAINDICATIONS
id: 415b3da7-3fb0-4a5f-e054-00144ff8d46c
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3
Spironolactone is contraindicated for patients with anuria, acute renal insufficiency, significant impairment of renal excretory function, hyperkalemia, Addison’s disease, and with concomitant use of eplerenone.
ADVERSE REACTIONS
id: 415b3da7-3fc9-4a5f-e054-00144ff8d46c
displayName: ADVERSE REACTIONS SECTION
FDA Article Code: 34084-4
The following adverse reactions have been reported and, within each category (body system), are listed in order of decreasing severity.
Digestive: Gastric bleeding, ulceration, gastritis, diarrhea and cramping, nausea, vomiting.
Reproductive: Gynecomastia (see
Precautions
), inability to achieve or maintain erection, irregular menses or amenorrhea, postmenopausal bleeding, breast pain. Carcinoma of the breast has been reported in patients taking spironolactone but a cause and effect relationship has not been established.
Hematologic: Leukopenia (including agranulocytosis), thrombocytopenia.
Hypersensitivity: Fever, urticaria, maculopapular or erythematous cutaneous eruptions, anaphylactic reactions, vasculitis.
Metabolism: Hyperkalemia, electrolyte disturbances (see
Warnings
and
Precautions
).
Musculoskeletal: Leg cramps.
Nervous system/psychiatric: Lethargy, mental confusion, ataxia, dizziness, headache, drowsiness.
Liver/biliary: A very few cases of mixed cholestatic/hepatocellular toxicity, with one reported fatality, have been reported with spironolactone administration.
Renal: Renal dysfunction (including renal failure).
Skin: Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS), alopecia, pruritus.
OVERDOSAGE
id: 415b3da7-3fca-4a5f-e054-00144ff8d46c
displayName: OVERDOSAGE SECTION
FDA Article Code: 34088-5
The oral LD
50 of spironolactone is greater than 1000 mg/kg in mice, rats, and rabbits.
Acute overdosage of spironolactone may be manifested by drowsiness, mental confusion, maculopapular or erythematous rash, nausea, vomiting, dizziness, or diarrhea. Rarely, instances of hyponatremia, hyperkalemia, or hepatic coma may occur in patients with severe liver disease, but these are unlikely due to acute overdosage. Hyperkalemia may occur, especially in patients with impaired renal function.
HOW SUPPLIED
id: 440aaee9-ca61-2908-e054-00144ff88e88
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5
Spironolactone tablets, USP are supplied as follows:
Spironolactone tablets 25 mg, white, round, unscored, debossed MP 35
Bottles of 30 NDC 66267-476-30
Bottles of 120 NDC 66267-476-91
PRINCIPAL DISPLAY PANEL – 25 mg Tablet Bottle Label
id: 440aaee9-ca5e-2908-e054-00144ff88e88
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4
